JNJ News 102.53 06/13/2014 05:07:58 Johnson & Johnson (JNJ)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Johnson & Johnson (JNJ) 102.53 $JNJ

Approvals, Agreements, Name Change, and Partnerships - Analyst Notes on Johnson & Johnson, Furiex Pharmaceuticals, Select Medical, CTI and Hill-Rom
PR Newswire - 7 mins ago
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), Select Medical Holdings Corporation (NYSE: SEM), CTI BioPharma Corp. (NASDAQ: CTIC) and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3701-100free.

Final Glance: Pharmaceuticals companies
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Final Glance: Medical Devices companies
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were down at the close of trading:

Corporate Action Network and Injured Women Call on Illinois Attorney General to Investigate Johnson & Johnson
Business Wire - Thu Jun 12, 5:25PM CDT
Corporate Action Network and Illinois women who have been seriously injured by pelvic mesh implants asked Illinois Attorney General Lisa Madigan to investigate Johnson & Johnson (JNJ) for its dangerous pelvic mesh implants, citing their personal health problems and costs incurred by Illinois taxpayers.

Corporate Action Network and Injured Women Call on Mississippi Attorney General to Investigate Johnson & Johnson
Business Wire - Thu Jun 12, 5:21PM CDT
Corporate Action Network and Mississippi women who have been seriously injured by pelvic mesh implants asked Mississippi Attorney General Jim Hood to investigate Johnson & Johnson (JNJ) for its dangerous pelvic mesh implants, citing their personal health problems and costs incurred by Mississippi taxpayers.

Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson...

Is FIFA World Cup Driving Host Hotels? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 3:55PM CDT
Host Hotels & Resorts' (HST) Latin American properties are expected to benefit from increased leisure demand at Rio de Janeiro driven by the FIFA World Cup.

Midday Glance: Pharmaceuticals companies
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Midday Glance: Medical Devices companies
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:

Avanir Gains - AVP-825 Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 11:10AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced that AVP-825 met the primary efficacy endpoint in phase III study (COMPASS).

Early Glance: Pharmaceuticals companies
AP - Thu Jun 12, 9:47AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Early Glance: Medical Devices companies
AP - Thu Jun 12, 9:47AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:

2014 Report on the International Smoking Cessation and Nicotine De-addiction Products (Nicotine Gums, Patches, Lozenges, Inhalers, Sprays, Sublingual, Zyban, Chantix, E-cigarettes) Market - Forecast to 2019
PR Newswire Europe - Thu Jun 12, 8:48AM CDT
DUBLIN, June 12, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/wjrggr/smoking_cessation [http://www.researchandmarkets.com/research/wjrggr/smoking_cessation]) has announced the addition of the "Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/wjrggr/smoking_cessation] report to their offering.

Medtronic Is Great but Its Stock Is Too Expensive for Now
at The Street - Thu Jun 12, 5:30AM CDT
Rumor of a merger pushed the price up. Investors should sit on their hands and wait for the stock to come down.

Relapsed Multiple Myeloma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg9nqn/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Kyowa Hakko Kirin - Sanofi - Eli Lilly and Company - GlaxoSmithKline - Genentech - Piramal Enterprises - Prolexys - Millennium - Novartis - Astellas - Exelixis - Celgene - Threshold - Synta - Acceleron - Altor BioScience - Arno - Stemline - Noxxon - Acetylon - Pharma - Janssen - AbbVie - Oncopeptides - Senhwa Biosciences For more information visit http://www.researchandmarkets.com/research/hg...d_multiple

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell

Jim Cramer's 'Mad Money' Recap: Forget Washington and Stay the Course
at The Street - Wed Jun 11, 7:20PM CDT
Nothing turns buyers into sellers faster than wrangling in Washington, Cramer says.

Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs  in 2013. Big drug companies, such as AbbVie,  Johnson & Johnson  , and Amgen  , offer...

Is Medtronic a Buy? What Analyst Day Revealed
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Jun 11, 4:05PM CDT
Medtronic 's June 6 analyst day was by no means light fare, as the company crammed quite a bit of information into more than seven hours. While action-oriented investors are likely disappointed that management's commentary would seem to...

Aduro BioTech Secures $55 Million Series C Financing
Business Wire - Wed Jun 11, 3:00PM CDT
Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced the closing of a $55 million Series C financing. New investor Johnson & Johnson Development Corporation (JJDC) joined the Morningside group and other new and existing investors in the transaction.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 78

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Operation Healing Forces Partners with Wounded Warrior

Updated Category News Views 104

Joining Forces for Special Operations Families When it comes to the heavy lifting of supporting Special Operations Forces (SOF) families, two powerhouses—Operation Healing Forces (OHF) and Wounded Warrior Project (WWP)—are doubling down. They’re not just tossing around good intentions. Oh no, they’re pulling out the stops with a solid partnership focused on...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 105

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 55

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 66

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 340

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 87

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 59

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 197

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading

Top 5 Most Recently Viewed Articles

Ringkjøbing Landbobank's Impressive Mid-Year Financial Update

Updated Category News Views 214

Ringkjøbing Landbobank's Financial Performance for 2025 In an exciting turn of events, Ringkjøbing Landbobank has shared its quarterly report for the first half of 2025, revealing remarkable financial outcomes that have caught the attention of analysts and stakeholders alike. Approval from Management The bank's board of directors, along with its general management, has...

Continue Reading
Mercy Medical Opens Center for Orthopedic Innovation

Updated Category News Views 42

Foot and Ankle Care Leap at Mercy Medical Mercy Medical Center in Baltimore is shaking things up in the orthopedic world. On August 10, 2026, they pulled the curtain back on the Center for Orthopedic Innovation, a place where the future of foot and ankle care is being molded. Led by renowned figure Dr. Lew Schon, they've crafted a cutting-edge space that’s all about...

Continue Reading
GECU's $4.9B Milestone: Navigating Regulatory Hurdles

Updated Category News Views 49

GECU's Bold Step: Merging with Bank of the Southwest When the gears of the financial world start grinding, there's no room for hesitation. GECU, one of the powerhouses when it comes to credit unions locally in Texas and New Mexico, has just snagged the regulatory green light to merge with the Bank of the Southwest. Talk about making moves—this transition's poised to...

Continue Reading
Taiwan's Economic Surge Driven by AI Innovations and Exports

Updated Category News Views 264

Economic Growth Outlook in Taiwan Taiwan has recently upgraded its economic growth forecast, reflecting its robust performance amid the ongoing AI revolution. As global appetite for AI-driven technology continues to surge, Taiwan is poised to reap substantial benefits. AI-Driven Exports In a remarkable display of economic resilience, Taiwan's exports skyrocketed almost...

Continue Reading
Exceptional Gold Intersections Reported at Keats Trench

Updated Category News Views 111

Major Discoveries in Gold Exploration New Found Gold Corp. (TSXV: NFG) (NYSE-A: NFGC) is thrilled to disclose impressive results from the second phase of channel sampling at Keats Trench as part of its ongoing exploration efforts at the Queensway Project. Highlights from Keats Trench Phase II The company noted exceptional intercepts in its sampling campaign, including...

Continue Reading